Cookies are important to the proper functioning of a site. To improve your experience, we use cookies to remember log-in details and provide secure log-in, collect statistics to optimize site functionality and deliver content tailored to your interest.
By continuing to use this site you are giving us your consent to do this. For more information you can read our Privacy Policy.

United States

May 19, 2020


Company adds artificial intelligence, high-tech image capture, and advanced data processing to further accelerate innovations for its world-class endoscopy portfolio

Lexington, Mass. – FUJIFILM Medical Systems U.S.A., Inc., a leading provider of endoscopic imaging solutions, and part of the greater Fujifilm Healthcare portfolio, has announced several global milestones and initiatives to advance the field of endoscopy and endoscopic health over the course of its passed fiscal year.

“Fujifilm is working diligently on a global scale to improve the quality and production of potentially life-saving endoscopy technologies, and we’re proud to share our latest advancements with the industry,” says Taisuke Fujita, General Manager of FUJIFILM Medical Systems U.S.A., Inc.—Endoscopy. “Some of our newest AI-driven ‘smart’ technologies in light control, tool hygiene, imaging and data retrieval aim to accelerate innovation in the world of endoscopic diagnostics and treatment.”

AI Advancements in Endoscopy
AI Supporting Colonic Polyp Detection
Improving the detection and characterization rates of difficult-to-discover lesions has been one of Fujifilm’s priority focus areas.

Recently, FUJIFILM Europe GmbH launched technology with the aim to support real time detection and characterization of colonic polyps during colonoscopies utilizing REiLI,2 the company’s global informatics and AI technology.

Leveraging AI for Product Development
In 2019, FUJIFILM Corporation announced the development of its “smart” endoscope manufacturing facility which employs AI and IoT technologies to achieve significant high-production efficiency. The facility manufactures endoscopes compatible with Fujifilm’s ELUXEO endoscopic video imaging system, which uses distinct light wavelengths for observation to support lesion detection & characterization.

This investment is expected to double the site’s production capacity, support the global increase in demand for next-generation endoscopic technology, and further drive Fujifilm’s commitment to the industry. Learn more about Fujifilm’s Smart Endoscopy facility in FUJIFILM Corporation’s press release here.

Commitment to Technology
10 Product Launches Fortify U.S. Endoscopy Portfolio
Fujifilm strengthened its offering in core GI and interventional GI as well as interventional pulmonary endoscopy with the launch of 10 new endoscopes in 2019.

Broadening its interventional product offering, Fujifilm launched:

For Pulmonary applications, Fujifilm introduced the EB-580S Standard and EB-580T Treatment bronchoscopes designed for the effective observation, diagnosis, and treatment of the trachea and bronchial tree.

Adding four new core GI scopes, Fujifilm’s 700 Series portfolio is fully equipped with Ultra-Slim, Standard, Zoom, and Therapeutic gastroscopes, and Slim, Adult, Standard, and Zoom colonoscopes. Designed for use with the company’s ELUXEO endoscopic imaging platform, Fujifilm’s 700 Series endoscopes are compatible with Linked Color Imaging (LCI) and Blue Light Imaging (BLI).

Expanding upon its now well-rounded GI product portfolio, Fujifilm also introduces solutions for Minimally Invasive Surgical Endoscopy, featuring its ELUXEO® Surgical System, with FHD/UHD 4K imaging platform that enables minimally invasive surgical endoscopy and advanced flexible endoscopy procedures to be performed using the same tower. The System is set to debut at the SAGES Surgical Conference, which has been rescheduled for August 12-15, 2020.

Instrument Acquisition Broadens Global Endoscopy Offering
In 2019, FUJIFILM Corporation announced the acquisition of medwork GmbH3, a company that develops, manufactures and markets instruments for therapeutic and diagnostic endoscopy. The company will be a 100%-owned subsidiary of Fujifilm group. 

The demand for minimally-invasive endoscopic examination and treatments are increasing globally due to its low strains on patients, and the market for endoscopic instruments is expected to have strong growth. To learn more about the medwork GmbH acquisition, read FUJIFILM Corporation’s press release here.

International Industry Recognition
iF Design Award Proves National Technology Recognition

FUJIFILM Corporation is proud to have been awarded the 2020 iF Design Award, sponsored by the iF International Forum Design, for 10 of its products spanning several industries, notably, the EG-740N utra-slim transnasal gastroscope.

The iF Design Award is a prestigious international design award, and is considered one of the top three in the world. This year, there were 7,298 entries from 56 countries and regions.

Fujifilm’s EG-740N ultra-slim transnasal gastroscope features a 5.8mm distal tip diameter and a 2.4mm working channel, and offers maximum performance in a lightweight design for treatment in both routine and complex cases. Design improvements for this, and other Fujifilm 700 Series Endoscopes, include: exceptional maneuverability, easy instrument identification and one-step connector and contact-free technology.

Click here to see Fujifilm’s EG-740N ultra-slim transnasal gastroscope on iF Design, and click here to read about the various other Fujifilm products recognized with iF Design Awards.

Through combination of light spectrum enhancement and advanced signal processing, LCI differentiates the red color spectrum, developed to enhance mucosal visualization.
FUJIFILM Medical Systems U.S.A., Inc. makes no representation that REiLI AI applications for Endoscopy are FDA cleared or commercially available in the United States.
Fujifilm makes no representation that medworks endoscopic instruments are FDA cleared or commercially available in the United States.


About Fujifilm
FUJIFILM Medical Systems U.S.A., Inc. is a leading provider of diagnostic imaging products and medical informatics solutions that meet the evolving needs of healthcare facilities both today and tomorrow. From an unrivaled selection of digital X-ray systems, to the comprehensive Synapse® Enterprise Imaging portfolio, to full-field digital mammography systems with digital breast tomosynthesis, and computed tomography solutions for oncology and radiology applications, Fujifilm has products that are ideal for any size imaging environment. FUJIFILM Medical Systems U.S.A., Inc. – Endoscopy supplies high quality, technologically advanced endoscopic imaging solutions and devices to the medical field. Fujifilm’s TeraMedica Division, the leading provider of vendor neutral, enterprise-wide solutions for unrestricted medical image management and the core to the Synapse Enterprise Imaging portfolio, enables improved patient care by connecting imaging content across the entire care continuum. FUJIFILM Medical Systems U.S.A., Inc. is headquartered in Lexington, Massachusetts. For more information please visit and

FUJIFILM Holdings Corporation in Tokyo, Japan, brings innovative solutions to a broad range of global industries by leveraging its depth of knowledge and fundamental technologies derived from photographic film. Its proprietary core technologies contribute to the fields of healthcare, graphic systems, highly functional materials, optical devices, digital imaging and document products. These products and services are based on its extensive portfolio of chemical, mechanical, optical, electronic and imaging technologies. For the year ended March 31, 2018, the company had global revenues of $23.0 billion, at an exchange rate of 106 yen to the dollar. Fujifilm is committed to responsible environmental stewardship and good corporate citizenship.  For more information, please visit:   


Danielle Brown